Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P100045/S091

CardioMEMS HF System; Merlin.net PCN HF Portal (Model MN6000); CardioMEMS Backend Web Application (Model CM4000); HF Clo

ABBOTT MEDICAL · Decision date Sep 30, 2026

MEDTECHLEDGER EXPLANATIONP100045/S091

What did the FDA approve?

On 2026-09-30, FDA recorded an approval decision on P100045/S091, a PMA supplement submitted by Abbott Medical under the real-time process pathway, with the stated reason being a change in design, components, specifications or material. The supplement covers proposed modifications to the Merlin.net Patient Care Network Heart Failure Portal (Model MN6000) and the CardioMEMS Backend Web Application (Model CM4000) that together make up the HF Cloud Software Version C2.1 update.

The underlying device is categorized as an implantable hemodynamic system within the cardiovascular specialty, product code MOM. This action concerns the software components named in the supplement statement rather than a new approval of the full CardioMEMS HF System. The source record does not describe the specific software changes, their technical rationale, or any supporting documentation, so those details remain unknown.

The record also does not include clinical performance data, labeling changes, or any determination about effects on patient management, and none should be inferred from the approval alone.

FDA approval order statement

proposed modifications to the Merlin.net Patient Care Network (PCN) Heart Failure (HF) Portal (Model MN6000) and the CardioMEMS Backend Web Application (Model CM4000), that comprise the HF Cloud Software Version C2.1 update.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Sep 30, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P100045/S091
Regulatory pathway
PMA supplement
Product code
MOM
Decision code
APPR
Decision date
Sep 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, hemodynamic, implantable.

Product code
MOM
FDA device class
3

For the original device and its historical approval scope, see PMA P100045. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P100045 · Original PMA

    CARDIOMEMS HF PRESSURE MEASUREMENT SYSTEM

  2. P100045/S091 received

    Application receipt date recorded by FDA.

  3. P100045/S092 · Related supplement

    CardioMEMS PA Sensor and Delivery System (CM2000); CardioMEMS HF System

  4. P100045/S093 · Related supplement

    CardioMEMS PA Sensor and Delivery System

  5. P100045/S091 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P100045. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100045

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA approvalMay 28, 2014FDA
ABBOTT MEDICALPMA supplementSep 11, 2026FDA
ABBOTT MEDICALPMA supplementSep 30, 2026FDA

Explore the linked device profile

Other records with product code MOM

Product / regulatory recordCompanyPathwayDecision dateSource
Endotronix, Inc.PMA supplementOct 29, 2026FDA
Endotronix, Inc.PMA supplementOct 20, 2026FDA
Endotronix, Inc.PMA supplementOct 16, 2026FDA
Endotronix, Inc.PMA supplementOct 14, 2026FDA
Endotronix, Inc.PMA supplementSep 25, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
387 Nerem St. NW, Suite #500, Atlanta, GA, 30313

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records